Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
Sangeun Jeon, Meehyun Ko, Jihye Lee, Inhee Choi, Soo Young Byun, Soonju Park, David Shum, Seungtaek Kim
Abstract
Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (IC 50 s), and in particular, two FDA-approved drugs—niclosamide and ciclesonide—were notable in some respects.
Topics & Concepts
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Drug2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)VirologyMedicinePharmacologyDrug approvalAntiviral drugIdentification (biology)BiologyInfectious disease (medical specialty)Internal medicineOutbreakBotanyDiseaseSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesInfluenza Virus Research Studies